TWI369354B - Cytokine inhibitors - Google Patents

Cytokine inhibitors

Info

Publication number: TWI369354B
Authority: TW; Taiwan
Prior art keywords: cytokine inhibitors; cytokine; inhibitors
Prior art date: 2003-03-10

Application number

TW093106043A

Other languages

English (en)

Other versions

TW200508225A (en

Inventor

Neil Moss

Mark Stephen Ralph

Ming Hong Hao

Zhaoming Xiong

Pier Francesco Cirillo

Donghong A Gao

Daniel R Goldberg

Abdelhakim Hammach

Victor Kamhi

Matthew Russell Netherton

Kevin Chungeng Qian

Lifen Wu

Original Assignee

Boehringer Ingelheim Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-03-10

Filing date

2004-03-08

Publication date

2012-08-01

2004-03-08 Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma

2005-03-01 Publication of TW200508225A publication Critical patent/TW200508225A/zh

2012-08-01 Application granted granted Critical

2012-08-01 Publication of TWI369354B publication Critical patent/TWI369354B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pain & Pain Management (AREA)
Psychiatry (AREA)
Diabetes (AREA)
Immunology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Endocrinology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Vascular Medicine (AREA)
Toxicology (AREA)
Psychology (AREA)
Ophthalmology & Optometry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Pulmonology (AREA)
Dermatology (AREA)

TW093106043A 2003-03-10 2004-03-08 Cytokine inhibitors TWI369354B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US45336403P	2003-03-10	2003-03-10

Publications (2)

Publication Number	Publication Date
TW200508225A TW200508225A (en)	2005-03-01
TWI369354B true TWI369354B (en)	2012-08-01

Family

ID=34192982

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW093106043A TWI369354B (en)	2003-03-10	2004-03-08	Cytokine inhibitors

Country Status (20)

Country	Link
US (2)	US7078419B2 (zh)
EP (1)	EP1631567A2 (zh)
JP (1)	JP4954701B2 (zh)
KR (1)	KR101084961B1 (zh)
CN (2)	CN101239972A (zh)
AR (1)	AR043528A1 (zh)
AU (1)	AU2004264409B2 (zh)
BR (1)	BRPI0408228A (zh)
CA (1)	CA2518774C (zh)
CL (1)	CL2004000469A1 (zh)
IL (1)	IL170740A (zh)
MX (1)	MXPA05009554A (zh)
MY (2)	MY138373A (zh)
NZ (1)	NZ542775A (zh)
PE (1)	PE20050308A1 (zh)
RU (2)	RU2394029C2 (zh)
TW (1)	TWI369354B (zh)
UY (1)	UY28222A1 (zh)
WO (1)	WO2005016918A2 (zh)
ZA (1)	ZA200506242B (zh)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7078419B2 (en) *	2003-03-10	2006-07-18	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
EP1479677A1 (en) *	2003-05-19	2004-11-24	Aventis Pharma Deutschland GmbH	New indole derivatives as factor xa inhibitors
WO2005046603A2 (en) *	2003-11-10	2005-05-26	Synta Pharmaceuticals, Corp.	Pyridine compounds
GB0403038D0 (en) *	2004-02-11	2004-03-17	Novartis Ag	Organic compounds
CA2560387C (en) *	2004-05-03	2013-09-24	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
EP1867646A1 (en) *	2004-05-03	2007-12-19	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
US7470692B2 (en) *	2004-08-25	2008-12-30	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
CA2608258A1 (en) *	2005-05-12	2006-11-23	Boehringer Ingelheim International Gmbh	Bis-amination of aryl halides
US20080021000A1 (en) *	2006-07-19	2008-01-24	Su Chen	Mixtures of and methods of use for polyunsaturated fatty acid-containing phospholipids and alkyl ether phospholipids species
AU2008312948C1 (en) *	2007-10-16	2012-08-09	Daiichi Sankyo Company, Limited	Pyrimidyl indoline compound
WO2010132999A1 (en) *	2009-05-21	2010-11-25	Chlorion Pharma, Inc.	Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
AU2011218167B2 (en) *	2010-02-17	2014-07-10	Amgen Inc.	Aryl carboxamide derivatives as sodium channel inhibitors for treatment of pain
EP2914265A4 (en)	2012-11-05	2016-04-13	Nant Holdings Ip Llc	SUBSTITUTED INDOL-5-OL COMPOUNDS AND THEIR THERAPEUTIC APPLICATIONS
EP2925750A1 (en)	2012-11-29	2015-10-07	Karyopharm Therapeutics, Inc.	Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
CN105377261B (zh)	2013-03-15	2017-12-15	南特生物科学公司	取代的吲哚‑5‑酚衍生物和它们的治疗应用
DK3016946T3 (da)	2013-07-03	2023-01-09	Karyopharm Therapeutics Inc	Substituerede benzofuranyl- og benzoxazolylforbindelser og anvendelser deraf
WO2015042414A1 (en)	2013-09-20	2015-03-26	Karyopharm Therapeutics Inc.	Multicyclic compounds and methods of using same
NZ729137A (en)	2014-08-04	2022-07-29	Nuevolution As	Optionally fused heterocyclyl-substituted derivatives of pyrimidine useful for the treatment of inflammatory, metabolic, oncologic and autoimmune diseases
AU2016308829A1 (en)	2015-08-18	2018-03-08	Karyopharm Therapeutics Inc.	(s,e)-3-(6-aminopyridin-3-yl)-n-((5-(4-(3-fluoro-3-methylpyrrolidine-1-carbonyl)phenyl)-7-(4-fluorophenyl)benzofuran-2-yl)methyl)acrylamide for the treatment of cancer
TW201718581A (zh)	2015-10-19	2017-06-01	英塞特公司	作為免疫調節劑之雜環化合物
SMT202200369T1 (it)	2015-11-19	2022-11-18	Incyte Corp	Composti eterociclici come immunomodulatori
MA44075A (fr)	2015-12-17	2021-05-19	Incyte Corp	Dérivés de n-phényl-pyridine-2-carboxamide et leur utilisation en tant que modulateurs des interactions protéine/protéine pd-1/pd-l1
SG10202005790VA (en)	2015-12-22	2020-07-29	Incyte Corp	Heterocyclic compounds as immunomodulators
WO2017117406A1 (en) *	2015-12-31	2017-07-06	Karyopharm Therapeutics Inc.	Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US10858347B2 (en)	2015-12-31	2020-12-08	Karyopharm Therapeutics Inc.	Multicyclic compounds and uses thereof
ES2906460T3 (es)	2016-05-06	2022-04-18	Incyte Corp	Compuestos heterocíclicos como inmunomoduladores
TW201808902A (zh)	2016-05-26	2018-03-16	美商英塞特公司	作為免疫調節劑之雜環化合物
SG11201811414TA (en)	2016-06-20	2019-01-30	Incyte Corp	Heterocyclic compounds as immunomodulators
MA45669A (fr)	2016-07-14	2019-05-22	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
ES2846833T3 (es)	2016-07-18	2021-07-29	Janssen Pharmaceutica Nv	Ligandos de obtención de imágenes de tau por PET
MA46045A (fr)	2016-08-29	2021-04-28	Incyte Corp	Composés hétérocycliques utilisés comme immunomodulateurs
MA47099A (fr)	2016-12-22	2021-05-12	Incyte Corp	Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
MX391981B (es)	2016-12-22	2025-03-21	Incyte Corp	Derivados de benzooxazol como inmunomoduladores.
WO2018119236A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Triazolo[1,5-a]pyridine derivatives as immunomodulators
PL3558990T3 (pl)	2016-12-22	2022-12-19	Incyte Corporation	Pochodne tetrahydroimidazo[4,5-c]pirydyny jako induktory internalizacji pd-l1
US20180179179A1 (en)	2016-12-22	2018-06-28	Incyte Corporation	Heterocyclic compounds as immunomodulators
UA128453C2 (uk)	2018-03-30	2024-07-17	Інсайт Корпорейшн	Гетероциклічні сполуки як імуномодулятори
PL3790877T3 (pl)	2018-05-11	2023-06-12	Incyte Corporation	Pochodne tetrahydroimidazo[4,5-c]pirydyny jako immunomodulatory pd-l1
WO2021030162A1 (en)	2019-08-09	2021-02-18	Incyte Corporation	Salts of a pd-1/pd-l1 inhibitor
CN115175734B (zh)	2019-09-30	2024-04-19	因赛特公司	作为免疫调节剂的吡啶并[3,2-d]嘧啶化合物
CA3160131A1 (en)	2019-11-11	2021-05-20	Incyte Corporation	Salts and crystalline forms of a pd-1/pd-l1 inhibitor
JP7746259B2 (ja)	2019-12-20	2025-09-30	ヌエヴォリューション・アクティーゼルスカブ	核内受容体に対して活性の化合物
JP2021098692A (ja)	2019-12-20	2021-07-01	ヌエヴォリューション・アクティーゼルスカブＮｕｅｖｏｌｕｔｉｏｎＡ／Ｓ	核内受容体に対して活性の化合物
US11613532B2 (en)	2020-03-31	2023-03-28	Nuevolution A/S	Compounds active towards nuclear receptors
US11780843B2 (en)	2020-03-31	2023-10-10	Nuevolution A/S	Compounds active towards nuclear receptors
US11351149B2 (en)	2020-09-03	2022-06-07	Pfizer Inc.	Nitrile-containing antiviral compounds
WO2022099018A1 (en)	2020-11-06	2022-05-12	Incyte Corporation	Process of preparing a pd-1/pd-l1 inhibitor
US11760756B2 (en)	2020-11-06	2023-09-19	Incyte Corporation	Crystalline form of a PD-1/PD-L1 inhibitor
MX2023005362A (es)	2020-11-06	2023-06-22	Incyte Corp	Proceso para hacer un inhibidor de proteina de muerte programada 1 (pd-1)/ligando de muerte programada 1 (pd-l1) y sales y formas cristalinas del mismo.

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4302051A1 (de)	1993-01-26	1994-07-28	Thomae Gmbh Dr K	5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5484944A (en) *	1993-10-27	1996-01-16	Neurogen Corporation	Certain fused pyrrolecarboxanilides and their use as GABA brain receptor ligands
GB9424379D0 (en)	1994-12-02	1995-01-18	Agrevo Uk Ltd	Fungicides
FR2732967B1 (fr)	1995-04-11	1997-07-04	Sanofi Sa	1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant
EP0881223A4 (en)	1996-02-09	1999-04-14	Kumiai Chemical Industry Co	BENZOFURANE-7-YLURACILE DERIVATIVES AND ASSOCIATED HERBICIDES
WO1998022452A1 (en)	1996-11-19	1998-05-28	Kyowa Hakko Kogyo Co., Ltd.	Benzofuran derivatives
AU749271B2 (en)	1997-07-01	2002-06-20	Agouron Pharmaceuticals, Inc.	Glucagon antagonists/inverse agonists
PT1042305E (pt) *	1997-12-22	2005-10-31	Bayer Pharmaceuticals Corp	Inibicao de quinase p38 utilizando difenilureias simetricas e assimetricas
AU3297099A (en)	1998-02-25	1999-09-15	Genetics Institute Inc.	Inhibitors of phospholipase a2
AU2641299A (en)	1998-03-04	1999-09-20	Kyowa Hakko Kogyo Co. Ltd.	Benzofuran derivatives
WO1999051580A1 (en)	1998-04-08	1999-10-14	Abbott Laboratories	Pyrazole inhibitors of cytokine production
JP2000026430A (ja) *	1998-07-02	2000-01-25	Taisho Pharmaceut Co Ltd	２、５、６−置換ベンズイミダゾール化合物誘導体
AU753360B2 (en)	1998-07-31	2002-10-17	Nippon Soda Co., Ltd.	Phenylazole compounds, process for producing the same and drugs for hyperlipemia
AU1130700A (en)	1998-10-23	2000-05-15	Dow Agrosciences Llc	Insecticidal 1-(substituted pyridyl)-1,2,4-triazoles
AU1707700A (en)	1998-10-29	2000-05-22	Bristol-Myers Squibb Company	Novel inhibitors of impdh enzyme
WO2000044737A1 (en)	1999-01-27	2000-08-03	Eli Lilly And Company	Aminoalkylbenzofurans as serotonin (5-ht(2c)) agonists
JP2000256358A (ja)	1999-03-10	2000-09-19	Yamanouchi Pharmaceut Co Ltd	ピラゾール誘導体
WO2000055152A1 (en) *	1999-03-12	2000-09-21	Boehringer Ingelheim Pharmaceuticals, Inc.	Aromatic heterocyclic compounds as anti-inflammatory agents
UA71971C2 (en)	1999-06-04	2005-01-17	Agoron Pharmaceuticals Inc	Diaminothiazoles, composition based thereon, a method for modulation of protein kinases activity, a method for the treatment of diseases mediated by protein kinases
ATE375334T1 (de) *	1999-11-16	2007-10-15	Boehringer Ingelheim Pharma	Harnstoff derivate als entzündungshemmende mittel
WO2001044445A2 (en)	1999-12-16	2001-06-21	Incyte Genomics, Inc.	Human lyases and associated proteins
WO2001051456A2 (en)	2000-01-13	2001-07-19	Tularik Inc.	Antibacterial agents
HN2001000008A (es)	2000-01-21	2003-12-11	Inc Agouron Pharmaceuticals	Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP5010089B2 (ja)	2000-09-19	2012-08-29	スピロジェンリミテッド	Ｃｃ−１０６５およびデュオカルマイシンのアキラルアナログの組成物およびその使用方法
AUPR034000A0 (en)	2000-09-25	2000-10-19	Fujisawa Pharmaceutical Co., Ltd.	Aminoalcohol derivatives
FR2815030A1 (fr)	2000-10-05	2002-04-12	Lipha	Derives nitroso de la diphenylamine, compositions pharmaceutiques les contenant et leur utilisation pour la preparation de medicaments
CA2443697A1 (en)	2001-04-13	2002-10-24	Pier F. Cirillo	1,4-disubstituted benzo-fused compounds
US6498423B1 (en)	2001-06-27	2002-12-24	Welch Allyn, Inc.	Lamp thermal control by directed air flow
US7297708B2 (en)	2001-09-06	2007-11-20	Bristol-Myers Squibb Company	Heteroaromatic substituted cyclopropane as corticotropin releasing hormone ligands
ES2367422T3 (es)	2001-10-09	2011-11-03	Amgen Inc.	Derivados de imidazol como agentes antiinflamatorios.
US20040248956A1 (en)	2002-01-29	2004-12-09	Hagmann William K	Substituted imidazoles as cannabinoid receptor modulators
EP1497278B1 (en) *	2002-04-11	2010-05-26	Boehringer Ingelheim Pharmaceuticals Inc.	Heterocyclic amide derivatives as cytokine inhibitors
US7078419B2 (en) *	2003-03-10	2006-07-18	Boehringer Ingelheim Pharmaceuticals, Inc.	Cytokine inhibitors
ATE482200T1 (de)	2003-05-01	2010-10-15	Bristol Myers Squibb Co	Als kinaseinhibitoren geeignete arylsubstituierte pyrazolamidverbindungen

2004
- 2004-02-27 US US10/789,354 patent/US7078419B2/en not_active Expired - Lifetime
- 2004-03-02 WO PCT/US2004/006264 patent/WO2005016918A2/en not_active Ceased
- 2004-03-02 CN CNA2008100835053A patent/CN101239972A/zh active Pending
- 2004-03-02 BR BRPI0408228-1A patent/BRPI0408228A/pt not_active IP Right Cessation
- 2004-03-02 CA CA2518774A patent/CA2518774C/en not_active Expired - Fee Related
- 2004-03-02 KR KR1020057016939A patent/KR101084961B1/ko not_active Expired - Fee Related
- 2004-03-02 MX MXPA05009554A patent/MXPA05009554A/es active IP Right Grant
- 2004-03-02 JP JP2006508971A patent/JP4954701B2/ja not_active Expired - Fee Related
- 2004-03-02 RU RU2005131167/04A patent/RU2394029C2/ru not_active IP Right Cessation
- 2004-03-02 CN CN2004800063518A patent/CN1759114B/zh not_active Expired - Fee Related
- 2004-03-02 AU AU2004264409A patent/AU2004264409B2/en not_active Ceased
- 2004-03-02 NZ NZ542775A patent/NZ542775A/en not_active IP Right Cessation
- 2004-03-02 EP EP04775820A patent/EP1631567A2/en not_active Withdrawn
- 2004-03-08 MY MYPI20040784A patent/MY138373A/en unknown
- 2004-03-08 PE PE2004000251A patent/PE20050308A1/es not_active Application Discontinuation
- 2004-03-08 TW TW093106043A patent/TWI369354B/zh not_active IP Right Cessation
- 2004-03-08 MY MYPI20080029A patent/MY149577A/en unknown
- 2004-03-08 UY UY28222A patent/UY28222A1/es not_active Application Discontinuation
- 2004-03-09 CL CL200400469A patent/CL2004000469A1/es unknown
- 2004-03-10 AR ARP040100759A patent/AR043528A1/es active IP Right Grant
2005
- 2005-08-04 ZA ZA200506242A patent/ZA200506242B/en unknown
- 2005-09-08 IL IL170740A patent/IL170740A/en not_active IP Right Cessation
2006
- 2006-06-27 US US11/426,603 patent/US7335657B2/en not_active Expired - Lifetime
2008
- 2008-03-03 RU RU2008107879/04A patent/RU2008107879A/ru not_active Application Discontinuation

Also Published As

Publication number	Publication date
US20040186114A1 (en)	2004-09-23
MY149577A (en)	2013-09-13
AR043528A1 (es)	2005-08-03
AU2004264409B2 (en)	2010-08-19
WO2005016918A2 (en)	2005-02-24
CN1759114A (zh)	2006-04-12
CA2518774A1 (en)	2005-02-24
IL170740A (en)	2011-06-30
CN1759114B (zh)	2013-04-10
AU2004264409A1 (en)	2005-02-24
JP2006519861A (ja)	2006-08-31
KR20050107792A (ko)	2005-11-15
CA2518774C (en)	2013-08-27
US20060235017A1 (en)	2006-10-19
UY28222A1 (es)	2004-11-08
US7078419B2 (en)	2006-07-18
NZ542775A (en)	2008-08-29
US7335657B2 (en)	2008-02-26
ZA200506242B (en)	2006-07-26
MY138373A (en)	2009-05-29
TW200508225A (en)	2005-03-01
PE20050308A1 (es)	2005-06-07
RU2008107879A (ru)	2009-09-10
KR101084961B1 (ko)	2011-11-23
EP1631567A2 (en)	2006-03-08
JP4954701B2 (ja)	2012-06-20
RU2394029C2 (ru)	2010-07-10
MXPA05009554A (es)	2005-10-19
CN101239972A (zh)	2008-08-13
CL2004000469A1 (es)	2005-01-14
BRPI0408228A (pt)	2006-02-21
RU2005131167A (ru)	2006-05-10
WO2005016918A3 (en)	2005-04-07

Publication	Publication Date	Title
TWI369354B (en)	2012-08-01	Cytokine inhibitors
IL174010A0 (en)	2006-08-01	Cytokine inhibitors
EG25482A (en)	2012-01-15	Inhibitors
EP1496910A4 (en)	2006-03-29	KINASE INHIBITORS
IL173381A0 (en)	2006-06-11	2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
AU2003271566A8 (en)	2004-03-03	Pyrrolopyrazines as kinase inhibitors
SI1569907T1 (sl)	2016-06-30	Na nikotinamidu osnovani kinazni inhibitorji
IL179398A0 (en)	2007-05-15	Dpp-ib inhibitors
EP1558609A4 (en)	2008-05-28	KINASE INHIBITORS
ZA200707086B (en)	2009-04-29	Cytokine inhibitors
AU2003217105A8 (en)	2003-09-16	Novel of cytokine inhibitors
EP1532133A4 (en)	2006-11-15	NF-: B INHIBITORS
GB2412372B (en)	2007-02-21	Pyrazine-based tubulin inhibitors
GB0310841D0 (en)	2003-06-18	Block
EP1569907A4 (en)	2007-10-31	NICOTINAMIDE-BASED KINASE HEMMER
GB0328261D0 (en)	2004-01-07	Improved cytokine design
EP1704142A4 (en)	2008-08-20	PROTEASE INHIBITORS
GB0421355D0 (en)	2004-10-27	Inhibitors
GB0311195D0 (en)	2003-06-18	Glyoxalase inhibitors
IL175569A0 (en)	2006-09-05	Cytokine antagonist molecules
GB0421356D0 (en)	2004-10-27	Inhibitors
GB0318913D0 (en)	2003-09-17	Apoptosis inhibitors
IL175151A0 (en)	2006-09-05	Bicyclic pyrazolone cytokine inhibitors
EP1593416A4 (en)	2008-03-05	BLOCK
GB0312619D0 (en)	2003-07-09	Complement inhibitors

Legal Events

Date	Code	Title	Description
2016-05-01	MM4A	Annulment or lapse of patent due to non-payment of fees